US Pharmacopeia 350d ago

Rethinking Risk: Closing Gaps in Nitrosamine Control What if your nitrosamine risk assessment is missing key variables? In this episode, Dr. Hemant Gandhi, Ph.D, and Dr. Arunima Pola explore the often-overlooked blind spots in nitrosamine evaluations- from analytical limitations to evolving regulatory expectations. 🔍 In this episode, you’ll learn: ▪️ Common gaps that compromise nitrosamine control strategies ▪️ Analytical and regulatory disconnects that need urgent alignment ▪️ How forward-looking companies are adapting to the complexity of nitrosamine assessment Whether you’re in QA, QC, Regulatory, or R&D, this discussion will equip you with insights to strengthen your approach.